183 related articles for article (PubMed ID: 15615715)
21. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
Youdim MB
J Neural Transm Suppl; 2003; (65):73-88. PubMed ID: 12946050
[TBL] [Abstract][Full Text] [Related]
22. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers.
Yamin G; Uversky VN; Fink AL
FEBS Lett; 2003 May; 542(1-3):147-52. PubMed ID: 12729915
[TBL] [Abstract][Full Text] [Related]
23. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
[TBL] [Abstract][Full Text] [Related]
24. Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.
Foguel D; Suarez MC; Ferrão-Gonzales AD; Porto TC; Palmieri L; Einsiedler CM; Andrade LR; Lashuel HA; Lansbury PT; Kelly JW; Silva JL
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9831-6. PubMed ID: 12900507
[TBL] [Abstract][Full Text] [Related]
25. Effects of nitration on the structure and aggregation of alpha-synuclein.
Uversky VN; Yamin G; Munishkina LA; Karymov MA; Millett IS; Doniach S; Lyubchenko YL; Fink AL
Brain Res Mol Brain Res; 2005 Mar; 134(1):84-102. PubMed ID: 15790533
[TBL] [Abstract][Full Text] [Related]
26. Effects of alpha-synuclein post-translational modifications on metal binding.
González N; Arcos-López T; König A; Quintanar L; Menacho Márquez M; Outeiro TF; Fernández CO
J Neurochem; 2019 Sep; 150(5):507-521. PubMed ID: 31099098
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
28. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.
Volles MJ; Lee SJ; Rochet JC; Shtilerman MD; Ding TT; Kessler JC; Lansbury PT
Biochemistry; 2001 Jul; 40(26):7812-9. PubMed ID: 11425308
[TBL] [Abstract][Full Text] [Related]
29. Copper(II)-induced self-oligomerization of alpha-synuclein.
Paik SR; Shin HJ; Lee JH; Chang CS; Kim J
Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):821-8. PubMed ID: 10359669
[TBL] [Abstract][Full Text] [Related]
30. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies.
Souza JM; Giasson BI; Chen Q; Lee VM; Ischiropoulos H
J Biol Chem; 2000 Jun; 275(24):18344-9. PubMed ID: 10747881
[TBL] [Abstract][Full Text] [Related]
31. Forcing nonamyloidogenic beta-synuclein to fibrillate.
Yamin G; Munishkina LA; Karymov MA; Lyubchenko YL; Uversky VN; Fink AL
Biochemistry; 2005 Jun; 44(25):9096-107. PubMed ID: 15966733
[TBL] [Abstract][Full Text] [Related]
32. Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease.
Tabner BJ; Turnbull S; El-Agnaf OM; Allsop D
Free Radic Biol Med; 2002 Jun; 32(11):1076-83. PubMed ID: 12031892
[TBL] [Abstract][Full Text] [Related]
33. Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain.
Lowe R; Pountney DL; Jensen PH; Gai WP; Voelcker NH
Protein Sci; 2004 Dec; 13(12):3245-52. PubMed ID: 15537754
[TBL] [Abstract][Full Text] [Related]
34. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
Wakabayashi K; Tanji K; Mori F; Takahashi H
Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
[TBL] [Abstract][Full Text] [Related]
35. Accelerated alpha-synuclein fibrillation in crowded milieu.
Uversky VN; M Cooper E; Bower KS; Li J; Fink AL
FEBS Lett; 2002 Mar; 515(1-3):99-103. PubMed ID: 11943202
[TBL] [Abstract][Full Text] [Related]
36. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation.
Jensen PH; Nielsen MS; Jakes R; Dotti CG; Goedert M
J Biol Chem; 1998 Oct; 273(41):26292-4. PubMed ID: 9756856
[TBL] [Abstract][Full Text] [Related]
37. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.
Li W; Lesuisse C; Xu Y; Troncoso JC; Price DL; Lee MK
J Neurosci; 2004 Aug; 24(33):7400-9. PubMed ID: 15317865
[TBL] [Abstract][Full Text] [Related]
38. Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease.
Hegde ML; Jagannatha Rao KS
Arch Biochem Biophys; 2003 Oct; 418(2):169-78. PubMed ID: 14522588
[TBL] [Abstract][Full Text] [Related]
39. Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain.
Crowther RA; Daniel SE; Goedert M
Neurosci Lett; 2000 Oct; 292(2):128-30. PubMed ID: 10998565
[TBL] [Abstract][Full Text] [Related]
40. Oxidative dimer formation is the critical rate-limiting step for Parkinson's disease alpha-synuclein fibrillogenesis.
Krishnan S; Chi EY; Wood SJ; Kendrick BS; Li C; Garzon-Rodriguez W; Wypych J; Randolph TW; Narhi LO; Biere AL; Citron M; Carpenter JF
Biochemistry; 2003 Jan; 42(3):829-37. PubMed ID: 12534296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
